VYNE Therapeutics Inc (NASDAQ:VYNE) shares, rose in value on Thursday, April 16, with the stock price up by 2.49% to the previous day’s close as strong demand from buyers drove the stock to $1.85.
Actively observing the price movement in the last trading, the stock closed the session at $1.80, falling within a range of $1.8 and $1.89. The value of beta (5-year monthly) was 1.372. Referring to stock’s 52-week performance, its high was $4.30, and the low was $1.44. On the whole, VYNE has fluctuated by 4.52% over the past month.
With the market capitalization of VYNE Therapeutics Inc currently standing at about $28.13 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-05.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 50k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VYNE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of VYNE currently trading nearly 11.08% and -9.40% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.21, while the 7-day volatility ratio is showing 8.21% which for the 30-day chart, stands at 10.74%. Furthermore, VYNE Therapeutics Inc (VYNE)’s beta value is 1.59, and its average true range (ATR) is 0.18.
A comparison of VYNE Therapeutics Inc (VYNE) with its peers suggests the former has fared considerably weaker in the market. VYNE showed an intraday change of 2.49% in last session, and over the past year, it shrunk by -23.55%%.
Data on historical trading for VYNE Therapeutics Inc (NASDAQ:VYNE) indicates that the trading volumes over the past 10 days have averaged 0.13 and over the past 3 months, they’ve averaged 127.40K. According to company’s latest data on outstanding shares, there are 14.83 million shares outstanding.
Nearly 16.66% of VYNE Therapeutics Inc’s shares belong to company insiders and institutional investors own 48.02% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.14 million shares as on 2025-03-31, resulting in a short ratio of 0.75. According to the data, the short interest in VYNE Therapeutics Inc (VYNE) stood at 90.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.12 million. The stock has fallen by -44.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VYNE stock heading into the next quarter.
